FT Vest美国股票深度缓冲主动型ETF-3月 DMAR 深 沪
等待开盘 05-18 09:30:00 美东时间
44.3451
-0.100
-0.23%
华盛通- 最 高44.40
- 今 开44.3402
- 成交量 5702股
- 最 低 44.2918
- 昨 收 44.4452
- 总市值 4.20亿
- 52周最高 44.49
- 市盈率 静 --
- 换手率 0.06%
- 52周最低 38.5101
- 委 比 -14.29%
- 总股本 947.50万
- 历史最高 44.49
- 量 比 0.54
- 振 幅 0.24%
- 历史最低 29.15
- 每 手 1
- 风险率 1.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
Fennec Pharmaceuticals (NASDAQ:FENC) released first-quarter financial results a...
05-14 21:32
Fennec Pharmaceuticals Q1 sales rise 73% on PEDMARK demand
Fennec Pharmaceuticals Q1 sales rise 73% on PEDMARK demand Overview US specialty pharma's Q1 product sales rose 73% yr/yr on higher PEDMARK adoption Company posted net income of $201,000, reversing a loss a year ago Growth driven by expanded field sales and increased demand for PEDMARK Outlook Compa
05-14 18:41
Artiva Biotherapeutics Stock Slides Despite Positive Trial Data
Artiva Biotherapeutics shares fall after Phase 2a rheumatoid arthritis data and a $300 million private placement announcement.
05-09 00:20
Bristol Myers Squibb Says European Commission Grants Approval To Sotyktu, Alone Or In Combination With Methotrexate, For Treatment Of Active Psoriatic Arthritis In Adults
In the pivotal Phase 3 POETYK PsA clinical trials, Sotyktu demonstrated superiority compared with placebo at Week 16 across multiple endpoints, including skin and joint symptoms, with improvements in quality of life as
05-08 19:00
BMS wins EU approval for Sotyktu to treat active psoriatic arthritis in adults
BMS wins EU approval for Sotyktu to treat active psoriatic arthritis in adults European Commission granted marketing authorization for Sotyktu (deucravacitinib) to treat active psoriatic arthritis in adults with inadequate response or intolerance to prior DMARD therapy. Label covers use as monothera
05-08 18:59
Avenue Supermarts Files Fiscal 2026 Investor Presentation with Stock Exchanges
Avenue Supermarts Ltd. ( ($IN:DMART) ) has issued an announcement. Avenue Super...
05-02 20:33
BRIEF-Landmark Bancorp Files Non-Timely 10-K With U.S. SEC
BRIEF-Landmark Bancorp Files Non-Timely 10-K With U.S. SEC April 1 (Reuters) - Landmark Bancorp Inc LARK.O : LANDMARK BANCORP INC FILES NON-TIMELY 10-K WITH U.S. SEC LANDMARK BANCORP - TO BEGIN INTERNAL PROBE WITH OUTSIDE COUNSEL INTO MISCONDUCT ALLEGATIONS INVOLVING NON-EXECUTIVE EMPLOYEE AT LANDMA
04-01 18:56
BRIEF-Coreweave Closes Landmark $8.5 Billion Financing Facility, Achieving First Investment-Grade Rated Gpu-Backed Financing
BRIEF-Coreweave Closes Landmark $8.5 Billion Financing Facility, Achieving First Investment-Grade Rated Gpu-Backed Financing March 31 (Reuters) - CoreWeave Inc CRWV.O : COREWEAVE CLOSES LANDMARK $8.5 BILLION FINANCING FACILITY, ACHIEVING FIRST INVESTMENT-GRADE RATED GPU-BACKED FINANCING Source text:
03-31 20:39
Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Fennec Pharmaceuticals (FENC) to release Q4 earnings on March 24. Analysts expect EPS of $0.04 and revenue of $14.73 million. Stock gained 1.8% on Monday.
03-24 04:40
Fennec Pharmaceuticals Settles PEDMARK Patent Litigation With Cipla; Blocking Generic Entry Until September 2033
Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the litigation between them
03-16 20:13
